MedTrace Logo

Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial

NCT05611632 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142318

Last updated 2026-04-14

No results posted yet for this study

Summary

The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are easier to treat.

The trial has enrolled approximately 140,000 participants who will be actively followed for approximately three years from the date of enrollment.

Conditions

Interventions

DEVICE

Multi-cancer early detection test (Galleri test)

Blood collection and multi cancer early detection testing with return of positive test results.

Sponsors & Collaborators

  • The Cancer Research UK Cancer Prevention Trials Unit at Queen Mary University of London (CPTU)

    collaborator UNKNOWN

  • GRAIL, Inc.

    lead INDUSTRY

Principal Investigators

  • Harpal Kumar · GRAIL, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
77 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2026-06-30
Completion
2030-07-31
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05611632 on ClinicalTrials.gov